3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Colorectal Neoplasms
20
Pancreatic Neoplasms
11
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Rectal Neoplasms
5
Colonic Neoplasms
5
Thyroid Neoplasms
4
Multiple Myeloma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Hematologic Neoplasms
3
Glioma
3
Breast Neoplasms
3
Bile Duct Neoplasms
3
Triple Negative Breast Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Carcinoma, Hepatocellular
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Stomach Neoplasms
1
Interventions
Gemcitabine
3
pembrolizumab
2
napabucasin
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
linifanib
1
durvalumab
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Pemetrexed
1
Paclitaxel
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
HhAntag691
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
trametinib
×
Gastrointestinal
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled